
Feature|Articles|June 10, 2026
Rising Star: Introducing Viha Vig, MBChB
Author(s)Lynda Charters, Viha Vig, MBChB
Finding satisfaction in ocular research—considerations about AI and enhanced datasets.
Advertisement
Advertisement
The desire to do research was primal for Viha Vig, MBChB, who watched her father, a chemical engineer, develop water- and fire-proof material from the time she was a teenager in India. “My journey in research started because I wanted to do something similar. I wanted to find things that can be helpful and make them available to communities,” Vig said. She is in the Murray-to-Mountains Rural Generalist Intern Training Program, Victoria, Australia, and completed her MBChB at the University of Auckland, New Zealand, in 2025.
Related to this article

Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.

Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.

June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.

Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.

The trial over-enrolled and finished approximately 4 months ahead of initial projections, with 52-week topline data now expected in the second half of 2027.

Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.
Advertisement
Advertisement


